Genus (GNS)

Sector:

Pharma and Biotech

Index:

FTSE 250

1,868.00p
   
  • Change Today:
    -30.00p
  • 52 Week High: 2,590.00p
  • 52 Week Low: 1,637.00p
  • Currency: UK Pounds
  • Shares Issued: 66.03m
  • Volume: 57,446
  • Market Cap: £1,233.49m
  • RiskGrade: 128

Genus slips despite bullish outlook and strong first half

By Oliver Haill

Date: Wednesday 28 Feb 2018

LONDON (ShareCast) - (ShareCast News) - Genus, the animal genetics specialist, reported strong profits growth for the first half of its financial year and was bullish about prospects for its recently launched Sexcel product, despite warning of more demanding year-on-year comparisons in the second half.
As well as more demanding year on year comparatives in the second half, chief executive Karim Bitar acknowledged that there were headwinds and said there would be continue investment in its gene editing platform and resistance-development plans.

"We anticipate performing in line with our expectations in the full year on a constant currency basis, but now expect actual currencies to be a headwind for the year," he said, putting the quantum at around £3m for the 2018 financial year.

Revenue in the six months to 31 December of £238.6m trotted 7% higher or 10% in constant currency thanks to 16% underlying sales growth in bull semen and 6% from the pig market.

As well as its own actions, Genus benefited from improved market conditions, helping total volumes grow 8%, with sexed semen up 32% and IVB embryos up 35%.

Operating profit including joint ventures grew 18% to £31.5m and adjusted profit before tax grew 16% to £29.0m. Basic earnings per share grew 34% to 40.9p.

Statutory PBT jumped 25% to £14.3m and EPS 419% to 69p. Statutory numbers includes net accounting movements in valuation of biological assets, which boosted EPS thanks to a £32.0m non-cash reduction in deferred tax liabilities following the US tax reforms, plus amortisation, share-based payment costs and exceptional items.

Sexcel, the FTSE 250 company's proprietary innovative sexed semen offering, has been well received by customers, said Bitar, with early indications of its performance in the field were encouraging. Sales of the Sexcel's IntelliGen technology have begun to third parties in Europe and India, enabling other bull studs to take advantage of the technology.

Bitar said bovine limb ABS continued its improved trend following actions taken last year, while porcine unit PIC continued to perform well, despite market headwinds in China.

The interim dividend was lifted 9.5%, which directors said was a reflection of their confidence in the group's prospects.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Genus Market Data

Currency UK Pounds
Share Price 1,868.00p
Change Today -30.00p
% Change -1.58 %
52 Week High 2,590.00p
52 Week Low 1,637.00p
Volume 57,446
Shares Issued 66.03m
Market Cap £1,233.49m
RiskGrade 128

Genus Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
96.04% below the market average96.04% below the market average96.04% below the market average96.04% below the market average96.04% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
53.64% below the market average53.64% below the market average53.64% below the market average53.64% below the market average53.64% below the market average
18.52% above the sector average18.52% above the sector average18.52% above the sector average18.52% above the sector average18.52% above the sector average
Income
86.4% below the market average86.4% below the market average86.4% below the market average86.4% below the market average86.4% below the market average
71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average
Growth
67.9% below the market average67.9% below the market average67.9% below the market average67.9% below the market average67.9% below the market average
64.71% below the sector average64.71% below the sector average64.71% below the sector average64.71% below the sector average64.71% below the sector average

What The Brokers Say

Strong Buy 5
Buy 2
Neutral 0
Sell 0
Strong Sell 0
Total 7
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Genus Dividends

  Latest Previous
  Interim Final
Ex-Div 29-Feb-24 09-Nov-23
Paid 28-Mar-24 08-Dec-23
Amount 10.30p 21.70p

Trades for 13-May-2024

Time Volume / Share Price
16:11 2 @ 1,866.00p
16:35 34,896 @ 1,868.00p
16:35 2 @ 1,868.00p
16:35 181 @ 1,868.00p
16:35 90 @ 1,868.00p

Genus Key Personnel

CFO Alison Henriksen
CEO Jorgen Kokke

Top of Page